However, in patients with liver iron concentration < 7 mg Fe/ g dw treated with EXJADE (5 and 10 mg/ kg) or deferoxamine (20 to 35 mg/ kg), non-inferiority was not established due to imbalance in the dosing of the two chelators.
http://www.emea.europa.eu/

Madankollu, f’ pazjenti li kellhom konċentrazzjoni tal- ħadid fil- fwied < 7mg Fe/ g dw kurati b’ EXJADE (5 u 10 mg/ kg) jew deferoxamine (20 sa 35 mg/ kg), ma ġiex stabbilit jekk ma kienx 31 inferjuri minħabba żbilanċ fid- dużaġġi taż- żewġ kelaturi.
http://www.emea.europa.eu/

It appeared from a post-hoc analysis of this study that, in the subgroup of patients with liver iron concentration ≥ 7 mg Fe/ g dw treated with EXJADE (20 and 30 mg/ kg) or deferoxamine (35 to ≥ 50 mg/ kg), the non-inferiority criteria were achieved.
http://www.emea.europa.eu/

Minn analiżi li saret wara dan l- istudju deher li, fis - sottogrupp tal- pazjenti li kellhom konċentrazzjoni tal- ħadid fil- fwied ≥7 mg Fe/ g dw kurati b’ EXJADE (20 u 30 mg/ kg) jew deferoxamine (35 sa ≥50 mg/ kg), il- kriterji li juru li ma kienx inferjuri intlaħqu.
http://www.emea.europa.eu/

In addition, in patients with liver iron concentration ≥ 7 mg Fe/ g dw with various rare anaemias or sickle cell disease, EXJADE up to 20 and 30 mg/ kg produced a decrease in liver iron concentration and serum ferritin comparable to that obtained in patients with beta-thalassaemia.
http://www.emea.europa.eu/

Minbarra hekk, f’ pazjenti b’ konċentrazzjoni tal- ħadid fil- fwied ta ’ ≥7 mg Fe/ g dw li kellhom diversi anemiji rari jew marda tas- sickle cell, meta ngħataw sa 20 u 30 mg/ kg EXJADE kien hemm tnaqqis fil- konċentrazzjoni tal- ħadid fil- fwied u tal- ferritin fis- serum li jikkumpara ma ’ dak li nkiseb f’ pazjenti b’ beta- talessimja.
http://www.emea.europa.eu/